UBE3A and Huntington disease: Evidence from cellular and animal models indicates that reduced UBE3A expression or activity impairs mHTT clearance [107], leading to enhanced aggregate formation, accelerated disease phenotypes, and shortened lifespan, whereas maintaining UBE3A function can mitigate proteostasis defects associated with HD [108].